Cynthia Campos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cynthia Campos has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Irina Yermilov
PHAR, 324 South Beverly Drive, Suite 350, Beverly Hills, California 90212, USA
2 shared publications - Michael S. Broder
ADVI Health, LLC, Washington, DC 20004, USA
2 shared publications - Sarah N. Gibbs
PHAR, 324 South Beverly Drive, Suite 350, Beverly Hills, California 90212, USA
2 shared publications A Patel
Genentech, Inc., South San Francisco, CA, USA
1 shared publicationAd Shapiro
Indiana Hemophilia & Thrombosis Center, Indianapolis, IN, USA
1 shared publication- Adriana Bastos Conforto
Hospital Israelita Albert Einstein, São Paulo, Brazil
1 shared publication
Latest Publications
- Open Access
- 15 March 2025
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 9 (5) , bvaf046
Osilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the ILLUSTRATE study
Context: In clinical trials, osilodrostat (11β-hydroxylase inhibitor) effectively reduced cortisol levels in patients with endogenous Cushing syndrome (CS). Objectives: A real-world study (ILLUSTRATE) was conducted evaluating osilodrostat use in patients with various etiologies of CS in the United States. Methods: A retrospective chart-review study was conducted of adults with CS treated with osilodrostat between May 1, 2020, and October 29, 2021. Results: A total of 42 patients (Cushing disease, n = 34; CS due to adrenal adenoma, n = 5; ectopic adrenocorticotropin syndrome [EAS], n = 3) were included. Starting doses were 2 mg twice daily in 27/42 patients (64.3%), maintenance doses were 2 mg twice daily in 6 of 9 patients (66.7%) attaining them. During osilodrostat treatment, urinary free cortisol (UFC) decreased below the upper limit of normal (ULN) in 14 of 20 patients (70.0%) with pretreatment UFC greater than the ULN. Osilodrostat response was observed across a range of doses (2-20 mg/day). In Cushing disease, median UFC and late-night salivary cortisol decreased from 3.03 and 2.39 × ULN, respectively, to 0.71 and 1.13 × ULN at last assessment in those with available data (n = 17 and 8, respectively). UFC decreased in all patients with adrenal CS or EAS with available data (n = 2 each). There were no unexpected safety signals; the most common adverse events (incidence ≥20%) were fatigue, nausea, and lower-extremity edema. Glucocorticoid withdrawal syndrome and/or adrenal insufficiency were reported in 12 of 42 patients (28.6%) after osilodrostat initiation, resulting in treatment discontinuation in 4. Conclusion: In routine practice with dosing individualized according to clinical condition, response, and tolerability, osilodrostat was effective and well tolerated regardless of CS etiology and severity.
- 15 March 2025
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 9 (5) , bvaf046
Open AccessOsilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the ILLUSTRATE study
Context: In clinical trials, osilodrostat (11β-hydroxylase inhibitor) effectively reduced cortisol levels in patients with endogenous Cushing syndrome (CS). Objectives: A real-world study (ILLUSTRATE) was conducted evaluating osilodrostat use in patients with various etiologies of CS in the United States. Methods: A retrospective chart-review study was conducted of adults with CS treated with osilodrostat between May 1, 2020, and October 29, 2021. Results: A total of 42 patients (Cushing disease, n = 34; CS due to adrenal adenoma, n = 5; ectopic adrenocorticotropin syndrome [EAS], n = 3) were included. Starting doses were 2 mg twice daily in 27/42 patients (64.3%), maintenance doses were 2 mg twice daily in 6 of 9 patients (66.7%) attaining them. During osilodrostat treatment, urinary free cortisol (UFC) decreased below the upper limit of normal (ULN) in 14 of 20 patients (70.0%) with pretreatment UFC greater than the ULN. Osilodrostat response was observed across a range of doses (2-20 mg/day). In Cushing disease, median UFC and late-night salivary cortisol decreased from 3.03 and 2.39 × ULN, respectively, to 0.71 and 1.13 × ULN at last assessment in those with available data (n = 17 and 8, respectively). UFC decreased in all patients with adrenal CS or EAS with available data (n = 2 each). There were no unexpected safety signals; the most common adverse events (incidence ≥20%) were fatigue, nausea, and lower-extremity edema. Glucocorticoid withdrawal syndrome and/or adrenal insufficiency were reported in 12 of 42 patients (28.6%) after osilodrostat initiation, resulting in treatment discontinuation in 4. Conclusion: In routine practice with dosing individualized according to clinical condition, response, and tolerability, osilodrostat was effective and well tolerated regardless of CS etiology and severity.
- Top Cited PapersOpen Access
- 13 November 2024
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 19 (1) , 83-94
Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America
- 13 November 2024
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 19 (1) , 83-94
Top Cited PapersOpen AccessDevelopment and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America
- Open Access
- 1 June 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 7 (7) , e2200715
Comprehensive Review on the Clinical Impact of Next-Generation Sequencing Tests for the Management of Advanced Cancer
PURPOSE: This review summarizes the published evidence on the clinical impact of using next-generation sequencing (NGS) tests to guide management of patients with cancer in the United States.METHODS: We performed a comprehensive literature review to identify recent English language publications that presented progression-free survival (PFS) and overall survival (OS) of patients with advanced cancer receiving NGS testing.RESULTS: Among 6,475 publications identified, 31 evaluated PFS and OS among subgroups of patients who received NGS-informed cancer management. PFS and OS were significantly longer among patients who were matched to targeted treatment in 11 and 16 publications across tumor types, respectively.CONCLUSION: Our review indicates that NGS-informed treatment can have an impact on survival across tumor types.
- 1 June 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 7 (7) , e2200715
Open AccessComprehensive Review on the Clinical Impact of Next-Generation Sequencing Tests for the Management of Advanced Cancer
PURPOSE: This review summarizes the published evidence on the clinical impact of using next-generation sequencing (NGS) tests to guide management of patients with cancer in the United States.METHODS: We performed a comprehensive literature review to identify recent English language publications that presented progression-free survival (PFS) and overall survival (OS) of patients with advanced cancer receiving NGS testing.RESULTS: Among 6,475 publications identified, 31 evaluated PFS and OS among subgroups of patients who received NGS-informed cancer management. PFS and OS were significantly longer among patients who were matched to targeted treatment in 11 and 16 publications across tumor types, respectively.CONCLUSION: Our review indicates that NGS-informed treatment can have an impact on survival across tumor types.
- 25 June 2022
- Published by Elsevier in Value in Health
- Vol. 25 (7) , S438-S439
EPH25 Claims-Based Algorithms to Identify Persons with Severe Hemophilia A
- 25 June 2022
- Published by Elsevier in Value in Health
- Vol. 25 (7) , S438-S439
EPH25 Claims-Based Algorithms to Identify Persons with Severe Hemophilia A
- 20 April 2009
- Vol. 29 (29) , 61-6
Institute for clinical management of nephrourological diseases: the benefits of a quality care programme
- 20 April 2009
- Vol. 29 (29) , 61-6
Institute for clinical management of nephrourological diseases: the benefits of a quality care programme
- Open Access
- 1 March 2003
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 61 (1) , 95-99
Treatment of subclavian steal syndrome with percutaneous transluminal angioplasty and stenting: case report
Subclavian steal syndrome refers to the association of neurological symptoms related to vertebrobasilar insufficiency and the phenomenon of subclavian steal. We report the case of a 63 year-old male patient that presented subclavian steal syndrome and severe proximal (80%) stenosis of the left subclavian artery. The patient was submitted to percutaneous transluminal angioplasty and stenting on the left SA. The procedure was well tolerated and immediately afterwards, there was complete remission of the symptoms and of the phenomenon of subclavian steal evaluated by angiography and transcranial doppler. We propose that percutaneous transluminal angioplasty with stenting placement is a good therapeutic option for subclavian steal syndrome.
- 1 March 2003
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 61 (1) , 95-99
Open AccessTreatment of subclavian steal syndrome with percutaneous transluminal angioplasty and stenting: case report
Subclavian steal syndrome refers to the association of neurological symptoms related to vertebrobasilar insufficiency and the phenomenon of subclavian steal. We report the case of a 63 year-old male patient that presented subclavian steal syndrome and severe proximal (80%) stenosis of the left subclavian artery. The patient was submitted to percutaneous transluminal angioplasty and stenting on the left SA. The procedure was well tolerated and immediately afterwards, there was complete remission of the symptoms and of the phenomenon of subclavian steal evaluated by angiography and transcranial doppler. We propose that percutaneous transluminal angioplasty with stenting placement is a good therapeutic option for subclavian steal syndrome.